Table 3.

Base-case cost-effectiveness results: pembrolizumab interventions versus KEYNOTE-048 trial comparator cetuximab + platinum + 5-FU

Costs and outcomes	Patient with CPS ≥ 1 Pembrolizumab monotherapy versus cetuximab + platinum + 5-FU			Total population Pembrolizumab combination versus cetuximab + platinum + 5-FU
	Comparator	Intervention	Incremental	Comparator	Intervention	Incremental
Costs, AR$
Treatments	5,149,867	5,045,882	− 103,985	5,189,755	5,791,572	601,817
Drug acquisition	3,808,172	4,224,319	416,147	3,933,060	4,669,354	736,295
Drug administration	94,052	82,107	− 11,945	94,836	215,432	120,595
Subsequent treatment	1,231,081	739,112	− 491,969	1,144,727	882,017	− 262,709
Adverse event	16,562	344	− 16,218	17,132	24,768	7636
Disease management	568,188	822,095	253,907	570,508	872,988	302,481
Pre-progression	206,851	259,415	52,564	200,068	258,383	58,316
Disease progression	24,268	24,149	− 119	24,207	24,183	− 25
Post-progression	158,109	365,631	207,522	165,580	421,278	255,697
Terminal care	178,960	172,901	− 6059	180,652	169,145	− 11,508
Total	5,718,055	5,867,977	149,922	5,760,262	6,664,560	904,298
Outcomes
Life-years	1.3439	2.4479	1.1040	1.3538	2.6834	1.3296
Quality-adjusted life years	1.0736	1.9504	0.8768	1.0803	2.1339	1.0536
Progression-free	0.5317	0.6823	0.1507	0.5123	0.6725	0.1602
Progressive disease	0.5519	1.2762	0.7243	0.5780	1.4705	0.8925
Adverse events	− 0.0010	0.0000	0.0010	− 0.0010	− 0.0010	0.0000
Time-to-death disutilities	− 0.0090	-0.0081	0.0009	− 0.0089	− 0.0081	0.0008
Cost-effectiveness ratio, AR$
Per life year			135,801			680,143
Per QALY			170,985			858,306

Ex-factory public prices from AlfaBeta, August 28, 2020

CPS combined positive score, 5-FU 5-fluorouracil, QALY quality-adjusted life-year AR $74 = 1 USD = 0.84 euro